Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
Archer Daniels Midland
downgraded at Credit Suisse to Neutral from Outperform. Largely a valuation call but also corn sweetener pricing power and buyback issues already played out, Credit Suisse said. Maintain $37 price target.
downgraded at Argus from Buy to Hold, Argus Research said. Valuation call.
( ARBA) downgraded at JMP from Outperform to Market Perform. Valuation call, as the stock is up more than 50% year-to-date.
upgraded at Baird from Neutral to Outperform, Robert Baird said. $41 price target. Recent quarter was an inflection point for the company, which will likely exceed 2011 expectations.
Corn Products International
( CPO) upgraded at Citi to Buy from Hold as acquisition of National Starch is a game changer. Price target goes to $51 from $44.
downgraded at Citi to Hold from Buy. Strong 3Q but valuation leads to downgrade, Citigroup said. Price target raised to $34 from $28.
downgraded at Piper to Neutral, Piper Jaffray said. Valuation call, based on a $30 price target.
downgraded at Deutsche to Hold, Deutsche Bank said. $125 price target. Company is facing potential growth headwinds in 2011.
estimate cut at Barclays. FSLR 2010 EPS estimate lowered to $7.55, 2011 held at $8.55. Beat and raise not enough, Barclays said. Maintain Equal Weight rating and $140 price target.
downgraded at Baird from Neutral to Underperform, Robert Baird said. $45 price target. Valuation call, as the stock is already pricing in moderate earnings growth.
downgraded at Citi to Sell from Hold. Back-end order cliff trumps big KLAC orders. Maintain $30 price target.
price target boosted at Credit Suisse to $44 from $35. Earnings power remains intact, valuation attractive. Maintain Outperform rating.
downgraded at Baird from Outperform to Neutral. $23 price target. Company lacks near-term catalysts.
upgraded at Ticonderoga to Buy from Neutral. Company should benefit from a cyclical market recovery.
upgraded at Citi to Buy from Hold on solid 3Q results and strong outlook, Citigroup said. Price target lifted to $221 from $17.
upgraded at FBR from Market Perform to Outperform. $29 price target. Estimates also boosted, to match the company's new guidance.
estimates, target lowered at Goldman. Shares of NUVA now seen reaching $24. Estimates also cut, given slowing market growth and increased competition in spinal implants. Neutral rating.
downgraded at William Blair to Market Perform. Estimates also cut, as the company cut guidance for the first time since its IPO.
upgraded at Argus from Hold to Buy. $53 price target. Company should see better demand and pricing for cruises.
downgraded at UBS from Buy to Neutral, UBS said. $54 price target. Estimates also cut, as the company is seeing lower volumes.
downgraded at Jefferies from Buy to Hold, Jefferies said. Orthopedic market remains challenged. $54 price target.
This article was written by a staff member of TheStreet.